Baystreet.ca RSS Feed http://www.baystreet.ca/rss/MasterRSS.aspx en-us Copyright (c) 2026 Baystreet.ca Inc. All rights reserved. 2/7/2026 9:14:16 AM <![CDATA[Primaris REIT "OUTPERFORM" ]]>Fri, 06 Feb 2026 11:59:00 ESThttps://www.baystreet.ca/articles/analyst_ratings.aspx?118384]]><![CDATA[Gold, Silver Set for Weekly Losses ]]>Fri, 06 Feb 2026 07:56:00 ESThttps://www.baystreet.ca/articles/commodities.aspx?id=8498Friday, February 6, 2026


Gold, Silver Set for Weekly Losses


Gold and silver rose on Friday, even as they headed for a second week of declines after a global tech stock rout and a stronger U.S. dollar wiped out the precious metals’ gains made during a brief rebound earlier this week.

Spot gold rose 1.1% to $4,822.69 U.S. per ounce early Friday, down 1.2% for the week. U.S. gold futures for April delivery fell 1% to $4,840.40 per ounce.

Spot silver was up 0.4% at $71.50 U.S. an ounce after a 19.1% drop in the last session.

Friday’s session was a volatile one for silver with prices rising as much as 3% after having fallen 10% to below the $65-level, a more-than-one-and-half-month low.

The white metal was down almost 16% for the week. Last week it shed 18% in its biggest weekly fall since 2011.

Spot platinum fell 3.6% to $1,916.60 U.S. per ounce after hitting an all-time high of $2,918.80 on January 26, while palladium gained 1.4% to $1,639.18. Both were down for the week.

]]>
<![CDATA[Duolingo Jumps on Announcing Q4 Earnings ]]>Thu, 05 Feb 2026 10:08:00 ESThttps://www.baystreet.ca/articles/techinsider.aspx?id=5403Thursday, February 5, 2026

Duolingo Jumps on Announcing Q4 Earnings


Duolingo, Inc. (NASDAQ: DUOL), the world's leading mobile learning platform, will announce its results for the fourth quarter and full year ending December 31, 2025, following the close of the U.S. market on Thursday, February 26, 2026. The Company will host a video webcast at 5:30 p.m. ET on that day.

The live video webcast will be accessible to the public through Duolingo’s Investor Relations website at https://investors.duolingo.com. A replay of the event will be available two hours after the live event and archived for one year.

Duolingo is the leading mobile learning platform globally. Its flagship app has organically become the world's most popular way to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. With technology at the core of everything it does, Duolingo has consistently invested to provide learners a fun, engaging, and effective learning experience while remaining committed to its mission to develop the best education in the world and make it universally available.

DUOL shares hiked $4.37, or 3.7%, to $121.27.

]]>
<![CDATA[Economic Calendar]]>Sat, 07 Feb 2026 09:14:15 ESThttps://www.baystreet.ca/articles/econ_calendar.aspx?id=18125February 2026
 

DATE

STATISTIC FOR CURRENT MONTH PREVIOUS MONTH
Monday, February 2, 2026 Markit Canada Manufacturing PMI 9:30 a.m. Jan Manufacturing PMI in Canada increased to 50.40 points in January from 48.60 points in December of 2025. The S&P Global Canada Manufacturing PMI inched higher to 48.6 in December of 2025 from 48.4 in the previous month
Friday, February 6, 2026 Labour Force Survey: 8:30am Jan Employment edged down in January (-25,000; -0.1%) and the employment rate decreased 0.1 percentage points to 60.8%. The unemployment rate fell by 0.3 percentage points to 6.5%, as fewer people searched for work. In December, employment was little changed (+8,200; 0.0%) and the employment rate held steady at 60.9%. The unemployment rate rose 0.3 percentage points to 6.8%, as more people searched for work.
Friday, February 6, 2026 IVEY Purchasing Managers Index: 10:00am Jan Ivey Purchasing Managers Index (PMI) data fell to 50.9 in January from rose to 51.9 last month. January 2025's reading was 47.1. Canadian economic activity expanded in December as employment increased at the fastest pace in 10 months, Ivey Purchasing Managers Index (PMI) data showed on Wednesday. The seasonally adjusted index rose to 51.9 last month from 48.4
Wednesday, February 11, 2026 Building Permits: 8:30am Dec --- In November, the total value of building permits issued in Canada decreased by $1.8 billion (-13.1%) to $12.0 billion.
Monday, February 16, 2026 Monthly Survey of Manufacturing: 8:30am Dec --- Manufacturing sales decreased 1.2% in November, driven by lower sales of motor vehicles, motor vehicle parts and machinery.
Monday, February 16, 2026 Housing Starts: 8:15am Jan --- Housing starts in China rose by 11% from the previous month to a seasonally adjusted of 282,439 in December of 2025, firmly above market expectations of 260,000, to mark the highest rate in five months.
Tuesday, February 17, 2026 Canada's International Transactions in Securities: 8:30am Dec --- Foreign investors added $16.3 billion of Canadian securities to their holdings in November, following a significant investment of $46.6 billion in October. Meanwhile, Canadian investors acquired $16.5 billion of foreign securities in November, more than offsetting the divestment of $11.6 billion in October.
Tuesday, February 17, 2026 Wholesale Trade: 8:30am Dec --- Wholesale sales (excluding petroleum, petroleum products, and other hydrocarbons and excluding oilseed and grain) fell 1.8% in November to $84.4 billion.
Tuesday, February 17, 2026 New Motor Vehicle Sales: 7:30am Dec --- In November, 150,832 new motor vehicles were sold in Canada, decreasing 6.6% from November 2024.
Tuesday, February 17, 2026 Consumer Price Index: 8:30am Jan --- CPI rose 2.4% year over year in December, up from an increase of 2.2% in November. On a seasonally adjusted monthly basis, the CPI rose 0.3% in December.
Wednesday, February 18, 2026 CREA MLS Sales: 8:30am Jan --- The number of home sales recorded over Canadian MLS® Systems declined 2.7% on a month -over-month basis in December 2025. On an annual basis, transactions totalled 470,314 units in 2025, a decrease of 1.9% from 2024. The year was characterized by a tariff -induced flight of buyers back to the sidelines in the first quarter, followed by a decent sales rally mid -year, and a bit of a stall to finish off 2025.
Thursday, February 19, 2026 Canadian International Merchandise Trade: 8:30am Dec --- Canada's monthly international trade in services surplus widened from $0.4 billion in September to $0.5 billion in October. Overall, imports of services declined 1.2% to $19.6 billion, and exports were down 0.4% to $20.1 billion.
Friday, February 20, 2026 Retail Trade: 8:30am Dec --- Retail sales increased 1.3% to $70.4 billion in November. Sales were up in eight of nine subsectors, led by increases at food and beverage retailers.
Friday, February 20, 2026 New Housing Price Index: 8:30am Jan --- The index decreased 0.2% in December, in comparison with an unchanged reading the month before.
Friday, February 20, 2026 Industrial Product Price Index: 8:30am Jan --- The Industrial Product Price Index decreased 0.6% month over month in December 2025 and gained 4.9% year over year.
Friday, February 20, 2026 Raw Materials Price Index: 8:30am Jan --- The Raw Materials Price Index increased by 0.5% month over month in December 2025 and rose 6.4% year over year.
Thursday, February 26, 2026 Payroll Employment, Earnings and Hours: 8:30am Dec --- In November, Canada's merchandise exports fell 2.8%, while imports edged down 0.1%. As a result, Canada's merchandise trade deficit with the world widened from $395 million in October to $2.2 billion in November.
Friday, February 27, 2026 GDP: 8:30am Dec --- Real gross domestic product was essentially unchanged in November.
Wednesday, March 18, 2026 BoC Interest Rate Decision: 9:45am Mar --- Wednesday, he Bank of Canada (BoC) held its key interest rate at 2.25%. The Bank Rate remains at 2.5%, while the deposit rate is 2.2%.
]]>
<![CDATA[Canada’s Unemployment Rate Fell To 6.5% In January ]]>Fri, 06 Feb 2026 09:21:00 ESThttps://www.baystreet.ca/articles/economiccommentary.aspx?id=4317Canada’s Unemployment Rate Fell To 6.5% In January


Canada’s unemployment rate fell by 0.3 percentage points to 6.5% in January of this year.

However, Statistics Canada said that employment across Canada decreased by 25,000 positions, or 0.1%, in January.

The unemployment rate declined during January because fewer people were searching for work, said the Ottawa-based statistical agency.

In January, employment fell by 27,000 positions among core-aged women (25 to 54 years old). There was little employment change among the other major demographic groups.

Across the economy, employment declines were broad based, with manufacturing positions falling 28,000, educational services losing 24,000 jobs, and public administration seeing 10,000 positions eliminated.

Those losses were offset by employment gains in information, culture, and recreation (up 17,000), business, building, and other support services (up 14,000), and agriculture (up 11,000).

Employment across Canada decreased by 67,000 jobs in Ontario, Canada’s most populous province. However, employment rose in Alberta (up 20,000) and Newfoundland (up 3,800).

Employment was little changed elsewhere in the country.

Average hourly wages among employees rose 3.3% year-over-year in January to $37.17 following growth of 3.4% in December.

]]>
<![CDATA[Asia Mostly Falls, Tracking N.A. Markets ]]>Fri, 06 Feb 2026 07:30:00 ESThttps://www.baystreet.ca/articles/foreignmarketwrap.aspx?id=4866Friday, February 6, 2026

Asia Mostly Falls, Tracking N.A. Markets


Asia markets mostly saw a weak session Friday, after a tech-led rout on Wall Street.

In Japan, the Nikkei 225 recovered 425.69 points, or 0.8%, to 54,253.68.

Shares of Japanese auto giant Toyota climbed 2% after the company released its third-quarter results, and announced that CEO Koji Sato was stepping down. Sato will be replaced by current Chief Financial Officer Kenta Kon.

Japanese pharmaceutical makers slumped on Friday, after U.S. President Donald Trump unveiled his website offering discounted prescription medicines. Sumitomo Pharma dropped almost 4%, while Takeda Pharmaceutical, Japan’s largest drugmaker, fell 1.34%.

In Hong Kong, the Hang Seng index shed 325.29 points, or 1.2%, to 26,559.85.

South Korea’s Kospi plunged as much as 5% at one point, but the index pared losses.

Index heavyweights Samsung Electronics and SK Hynix fell 0.44% and 0.36%, respectively, while Hyundai Motor was 4.3% lower.

Defense heavyweight Hanwha Aerospace was 3.75% down, while LG Energy Solution lost 2.53%.

South Korea’s market, which is heavily weighted in favor of companies in the chip and automotive industries, have seen sharp swings in the past week as sentiment over tech stocks sours.

Australia led losses in the region, ending at its lowest level in almost a month.

In other markets

The CSI 300 in Shanghai lost 28.26 points, or 0.6%, to 4,670.42.

In Korea, the Kospi dwindled 74.43 points, or 1.4%, to 5,089.14.

In Taiwan, the Taiex dropped 17.35 points, or 0.1%, to 31,782.92.

In Singapore, the Straits Times Index faded 18.35 points, or 0.1%. to 4,034.41.

In Australia, the ASX fell 180.39 points, or 2%, to 8,708.83.

In New Zealand, markets were closed for holiday.


]]>
<![CDATA[Bank of England Holds Interest Rates Steady ]]>Thu, 05 Feb 2026 09:30:00 ESThttps://www.baystreet.ca/articles/globalmarkets.aspx?id=3719The Bank of England has elected to hold its benchmark interest rate at 3.75%.

The central bank’s Monetary Policy Committee voted 5-4 to keep rates on hold for the time being. Four committee members voted to lower interest rates by 25 basis points.

Economists polled by Reuters (TRI) had expected the vote to be 7-2 in favour of leaving interest rates unchanged.

The Bank of England previously cut interest rates last December, but economists had expected the central bank to move to the sidelines in February given persistent inflation.

The latest data showed that inflation in the United Kingdom was at an annualized 3.4% in December, above the central bank’s 2% target.

The Bank of England said that monetary policy is being set to ensure that the inflation rate “not only reaches 2% but remains sustainably at that level.”

The British currency, the Pound sterling, was trading 0.6% lower against the U.S. dollar immediately after the rate decision was announced.

Futures markets are pricing in three 25 basis point interest rate cuts from the Bank of England this year.

]]>
<![CDATA[TSXV New Listings]]>Wed, 12 Feb 2025 06:30:00 ESThttps://www.baystreet.ca/articles/ipo_tsx.aspx?id=10023 Company Name Ticker Date AMV II Capital Corporation AMV.P 12-02-2025 Luxor Metals Ltd. LUXR 30-05-2025 Mawson Gold Limited MAW 04-01-2024 Axo Copper Corp. AXO 04-06-2025 Oa Capital Corp. OACP 09-01-2024 Artrari One Capital Corp. AOCC.P 05-01-2024 Euromax Resources Ltd. EOX 09-01-2024 Power One Resources Corp. PWRD 18-01-2024 Zodiac Gold Inc. ZAU 29-01-2024 Amaya Big Sky Capital Corp. AMYA.P 30-01-2024 Coco Pool Corp. CCPC.P 08-02-2024 Goldgroup Mining Inc. GGA 20-02-2024 Navion Capital II Inc. NVN.P 29-02-2024 Atha Energy Corp. SASK 04-03-2024 Sitka Gold Corp. SIG 05-03-2024 Coniagas Battery Metals Inc. cOS 18-03-2024 Kubera Gold Corp. KBRA 13-03-2024 Hypercharge Networks Corp. HC 28-03-2024 Valleyview Resources Ltd. VVR 28-03-2024 Tokens.com Corp. COIN 28-03-2024 Oracle Commodity Holding Corp. ORCL 05-04-2024 Kootenay Resources Inc. KTRI 01-05-2024 OnGold Resources Ltd. ONAU 08-05-2024 Chicane Capital II Corp. CHII.P 27-05-2024 Mogotes Metals Inc. MOG 12-06-2024 Nations Royalty Corp. NRC 21-06-2024 AuMega Metals Ltd AUM 26-06-2024 AC/DC Battery Metals Inc. ACDC 27-06-2024 Chablis Capital Corp. CCZ.P 28-06-2024 Treasury Metals Inc. TML 05-07-2024 Rua Gold Inc. RUA 29-07-2024 Florida Canyon Gold Inc. FCGV 16-07-2024 High Arctic Overseas Holdings Corp. HOH 16-08-2024 Borealis Mining Company Limited BOGO 07-08-2024 Culico Metals Inc. CLCO 16-08-2024 Mawson Finland LImited MFL 19-08-2024 Vizsla Royalties Corp. VROY 26-08-2024 Greenheart Gold Inc. GHRT 06-09-2024 Fiddlehead Resources Corp. FHR 10-09-2024 BIGG Digital Assets Inc. BIGG 17-09-2024 Saga Metals Corp. SAGA 23-09-2024 Mithril Silver and Gold Limited MSG 27-09-2024 International Battery Metals Ltd. IBAT 07-10-2024 Conavi Medical Corp. CNVI 16-10-2024 Metavista3D Inc. DDD 28-10-2024 CanCambria Energy Corp. CCEC 29-10-2024 Silver47 Exploration Corp. AGA 14-11-2024 Zero Candida Technologies Inc. ZCT 25-11-2024 Lombard Street Capital Corp. LSC.P 28-11-2024 Nickel Creek Platinum Corp. NCP 23-12-2024 Nevada Lithium Resources Inc. NVLH 31-12-2024 Scandium International Mining Corp. SCY 04-02-2025 Lotus Creek Exploration Inc. LTC 11-02-2025 Fraser Big Sky Capital Corp. FRAS.P 25-02-2025 Cerro de Pasco Resources Inc. XDPR 14-03-2025 F4 Uranium Corp. FFU 25-03-2025 Gold Hart Copper Corp. HART 21-03-2025 GreenLight Metals Inc. GRL 14-04-2025 BluEnergies Ltd. BLU 14-04-2025 Core Nickel Corp. CNCO 07-05-2025 Versamet Royalties Corporation VMET 20-05-2025 Sprock-It Acquisitions Ltd. SPRO.P 09-05-2025 Vinland Lithium Inc. VLD 23-05-2025 Kirkstone Metals Corp. KSM 23-05-2025 Adagio 2 Capital Inc. ADAD.P 12-06-2025 FinEx Metals Ltd. FINX 18-06-2025 Atlas Energy Corp. ATLE 24-06-2025 Bitcoin Treasury Corporation BTCT 26-06-2025 XTAO Inc. XTAO.U 22-07-2025 Almaden Minerals Ltd. AMM 13-08-2025 Pecoy Copper Corp. PCU 08-09-2025 River Road Resources Ltd. RRRL 17-09-2025 River Road Resources Ltd. RRRL 18-09-2025 Chrysalis 12 Inc. RTO.P 03-10-2025 Perseverance Metals Inc. PMI 14-10-2025 Matchpoint Ventures Corp. MPV.P 20-10-2025 Essex Resources Corp. ESXR 23-10-2025 Apolo V Acquisition Corp. AFV.P 24-10-2025 Summit Royalties Ltd. SUM 10-11-2025 Atlantic Horizon Capital Corp. ATLH.P 12-11-2025 Andina Copper Corporation ANDC 24-11-2025 Paragon Advanced Labs Inc. PALS 11-12-2025 LunR Royalties Corp. LUNR 19-12-2025 Buffalo Potash Corporation BUFF 06-01-2026 EnviroGold Global Limited NVRO 04-02-2026]]><![CDATA[Markets Climb to Near-Record Levels ]]>Fri, 06 Feb 2026 04:39:00 ESThttps://www.baystreet.ca/articles/marketupdates.aspx?id=14802Friday, February 6, 2026

16:39 PM EST
Markets Climb to Near-Record Levels

Broadcom, Palantir Make Presence Felt



Markets across North America celebrated a glorious end of the week, with major gains. And stocks in Canada joined in the party, on the backs of gold and material shares.

The TSX popped 476.38 points, or 1.5%, to conclude Friday at 32,470.98. On the week, the index gained 547 points, or 1.7%.

The Canadian dollar climbed 0.3 cents to 73.23 cents U.S.

In corporate news, Saputo reported third-quarter revenue after the bell on Thursday that missed analysts' estimates, while energy firm Arc Resources' fourth-quarter revenue beat estimates.

Saputo shares gained 22 cents to $42.74.

Capstone Copper said on Friday that full operations have resumed at Chile's Mantoverde mine following an end to a labour strike. Capstone shares regained 79 cents, or 5.3%, to $15.72.

Gold issues proved the kings, with New Gold jumping $1.55, or 12%, to $14.48, while Novagold captured $1.18, or 10.4%, to $12.56.

In materials, Discovery Silver picked up 85 cents, or 19.5%, to $9.76, while Endeavour Silver soared $1.21, or 8.5%, to $15.52.

In health-care plays, Curaleaf improved 29 cents, or 9.7%, to $3.27, while Bausch Health Companies gained 19 cents, or 2.4%, to $8.03.

On the economic front, Statistics Canada says Employment edged down in January by 0.1% and the unemployment rate fell by 0.3 percentage points to 6.5%, as fewer people searched for work.

Ivey Purchasing Managers Index (PMI) data fell to 50.9 in January from rose to 51.9 last month. January 2025's reading was 47.1.

ON BAYSTREET

The TSX Venture Exchange spiked 45.69 points, or 4.7%, to 1,015.34. The Venture struggled during the week, and is 34.74 points, or 3.3%, below last Friday’s close.

All 12 TSX subgroups were higher, with gold brighter by 4.8%, materials up 3.9%, and health-care better by 2.4%.

ON WALLSTREET

Stocks surged on Friday as technology stocks recovered following several days of heavy selling in the sector and bitcoin rebounded following
a rout that took the popular cryptocurrency down more than 50% at one point.

The Dow Jones Industrials charged ahead 1,206.95 points, or 2.5%, to 50,115.67, exceeding the 50,000 level for the first time ever and turning positive for the week.

The S&P 500 index triumphed 133.90 points, or 2%, to 6,932.30. With those moves, the S&P 500 climbed slightly back into the green for 2026.

The NASDAQ popped 490.63 points, or 2.2%, to 23,031.73.

Even with Friday’s pop, the S&P 500 was still on pace for a 0.1% decline for the week, while the NASDAQ is down almost 2% on the week.

The 30-stock Dow, meanwhile, is sitting up 2.5% week to date, benefitting from some rotation into some economically cyclical stocks even as the overall market was weighed down by tech selling.

Nvidia and Broadcom were two of the key winners Friday, with the former increasing by 8% and the latter growing 7% following big declines earlier in the week. Other stocks such as Oracle and Palantir Technologies also bounced back as investors reconsidered some of the names at cheaper levels. Oracle and Palantir each rose 4%. Some key software stocks like ServiceNow — which has been the epicenter of the tech selloff because of an artificial intelligence disruption fear of software — remained weak on Friday, however.

Amazon was an outlier Friday, as shares sank 6% after the e-commerce giant posted earnings per share slightly under analyst expectations and told investors to expect $200 billion in capital expenditures this year.

Prices for the 10-year Treasury dipped slightly, raising yields to 4.21% from Thursday’s 4.20%. Treasury prices and yields move in opposite directions.

Oil prices recovered 16 cents to $63.45 U.S. a barrel.

Gold prices recovered $85.20 to $4,974.70 U.S. an ounce.




]]>
<![CDATA[Stocks in Play: Harvest Portfolios Group Inc]]>Fri, 06 Feb 2026 12:10:28 ESThttps://www.baystreet.ca/articles/stocksinplay.aspx?id=46470Friday, February 6, 2026

12:10 PM EST - Harvest Portfolios Group Inc : Announced that the Harvest Healthcare Leaders Income ETF (HHL:TSX) “HHL” has been named a 2025 FundGrade A+® Award winner by Fundata Canada Inc. Harvest Portfolios Group Inc (T.HHL ) shares were up $0.09 at 7.62.

]]>
<![CDATA[Why Amazon Stock Dropped By 8%]]>Fri, 06 Feb 2026 11:01:00 ESThttps://www.baystreet.ca/articles/stockstowatch.aspx?id=22647Friday, February 6, 2026

Why Amazon Stock Dropped By 8%


Amazon (AMZN), among the Magnificent Seven, posted quarterly results that sent shares down this morning. AMZN stock lost 8% after setting a capital expenditure that rivals that of Microsoft (MSFT).
Amazon earned $1.95 per share as revenue increased by 13.6% Y/Y to $213.4 billion. Despite net sales of up to $178.5 billion expected in the first quarter of 2025, operating income will dip. It is expecting operating income to come in between $16.5 billion and $21.5 billion, compared to the $18.4 billion reported in Q1/2025.
Amazon plans to spend $200 billion this year in capital expenditures. Investors assumed that artificial intelligence investments were adding to those costs. However, the expenditure is predominantly in AWS for core and AI workloads. Since it is monetizing capacity as fast as the company installs the hardware, the firm should grow AWS revenue as long as AI demand continues.
Amazon is expecting that AWS will have a 35% operating margin through the fourth quarter, up by 40 bps Y/Y. Still, risks are rising that depreciation costs might grow faster than margin growth. As competition rises from more AI data center supply for Oracle (ORCL) and other middleware firms, AMZN stock could face more selling pressure.

]]>
<![CDATA[USD / CAD - Canadian dollar in a rut]]>Fri, 06 Feb 2026 02:44:11 ESThttps://www.baystreet.ca/articles/forex_trader.aspx?id=118388- Equites attempting a rally.

- Macklem suggests Canadian rates are not going lower

- US dollar opens with small losses.

USDCAD open: 1.3686, overnight range 1.3678-1.3725, close 1.3713, WTI 63.47, Gold 4879.76

The Canadian dollar traded sideways albeit with a modest bid in overnight markets.

Canada is forecast to have added about 7,000 jobs in January versus 8,200 in December, with the unemployment rate seen holding at 6.8%, although severe winter weather may have distorted the data.

Yesterday, Bank of Canada Governor Tiff Macklem cautioned that the economy is undergoing a structural shift rather than a routine cyclical slowdown. He blamed it on U.S. protectionism, slower population growth and the advance of artificial intelligence. He noted that growth is expected to be subdued, labour market adjustments uneven and productivity gains slow to materialize. He emphasised that monetary policy cannot resolve these forces, reinforcing expectations that Canadian interest rates will remain on hold for the foreseeable future.

WTI oil bounced around in a 62.32-64.58 range as US and Iran talks continue in Oman.

Thursday’s US jobs data showed a sharply higher increase in weekly jobless claims and a drop in job openings, clear evidence of a cooling job market. It may get even cooler. Amazon announced it was cutting 40,000 jobs while investing $200 billion to expand AI capabilities. US companies announced 108,000 layoffs in January.

Asian equities closed mixed, with Australia’s ASX 200 losing 2.03% due to fallout from the global tech stock plunge and soft commodity prices. Japan’s Topix rallied 1.28% in anticipation of new stimulus following Sunday’s election. Hong Kong’s Hang Seng lost 1.21% due to the fallout from the tech stock rout.

As of 7:30 am, European bourses are higher led by the German DAX has which is up 0.65%. The UK FTSE 100 has gained 0.20% and the French CAC 40 is nearly unchanged. S&P 500 futures have risen by 0.51%, the US Dollar Index is 97.83 and the 10-year Treasury yield is 4.201

EURUSD traded in a 1.1766–1.1802 range and firmed due to broad US dollar weakness following yesterday’s weak American data and a very content-sounding European Central Bank. President Christine Lagarde said the impact of the exchange rate gains is “incorporated into the baseline.”

German industrial production data was mixed, falling 1.9% m/m in December while the year-over-year figure beat expectations, although it remained negative at -0.6% y/y.

GBPUSD firmed in a 1.3509–1.3584 range and is sitting near the top of the band despite a somewhat dovish Bank of England policy meeting yesterday. The benchmark rate was left unchanged at 3.75% in a split decision and analysts are suggesting rates will be lowered in March.

USDJPY bounced in a 156.53–157.08 range and moved higher due to caution ahead of the February 8 election and modest but broad-based US dollar weakness.

AUDUS climbed in a 0.6897–0.6979 range and rallied as it erased yesterday’s losses. The RBA Governor explained the rationale for the latest rate hike from 3.60% to 3.85% to parliament, blaming the rise in inflation on low unemployment, higher incomes, lower interest rates, tax cuts and government spending. The intraday technicals are modestly bullish above 0.6910 and targeting 0.7050.



]]>
<![CDATA[Citigroup Vaults On Beating Quarterly Projections]]>Thu, 12 Oct 2017 10:07:02 ESThttp://www.baystreet.ca/articles.aspx?id=38460Earnings per Share came in for the quarter at $1.42, as opposed to $1.32 expected by experts. Revenue was $18.173 billion versus $17.896 billion expected. Fixed income trading: $2.877 billion versus a projected $2.84 billion

Said CEO Michael Corbat, "We had revenue increases in many of the products we have been investing in, tightly managed our expenses, and again saw loan growth in both our consumer and institutional businesses.”

Citi reported a 3% year-over-year increase in global consumer banking revenue. In North America, retail banking revenue rose 12%, excluding mortgages. Citi cited "continued growth in loans and assets under management," as well as higher interest rates.

The bank's international consumer business saw an 8% revenue increase, driven by higher loans and deposit volumes growth.

Citi's end-of-period loans, meanwhile, rose 2% to $653 billion, while deposits increased by 3% to $964 billion.

Shares of Citigroup have risen 26% this year, easily outperforming the broader market. The S&P 500 has gained 14% in 2017.

Citigroup's stock has also outperformed those of other big banks. Shares of JPMorgan Chase and Bank of America are up 11.9% and 16.9%,, respectively.

Folks who follow macroeconomic developments are also aware that Citigroup could benefit from tighter monetary policy in the near future. The U.S. Federal Reserve signaled a December rate hike in the summary of its Sept. 20 meeting.
Shares in C opened Thursday took on 31 cents to $75.25. ]]>
<![CDATA[Enterprise Group’s Hart Oilfield Rentals: Custom, Cost-Effective Infrastructure]]>Thu, 12 Oct 2017 09:51:46 ESThttp://www.baystreet.ca/articles.aspx?id=38459


Simply, if you are building a mining or oil business Hart rents customized equipment for project sites, drilling & completions and facilities that require mobile infrastructure.

It makes zero sense to expend valuable capital to purchase generators, offices, WC’s etc. As well, each project is different so flexibility, customization and ease of transport is key.



“Our large competitive advantage is the ability to what we refer to as ‘combo technology,” states Joel Bardwell, Senior Manager at Hart. “Whether on a skid or one of our proprietary portable trailers, we can deliver not only the equipment required, but customize it to be the most cost effective. Customers appreciate the approach and with our ongoing R&D and patent/patent pending profile, both served us well during the downturn and positions us well for the rapidly increasing business, both from previous and new clients.”

Hart currently has 6 locations that are strategically located throughout west central and northern Alberta and northeastern British Columbia. These 6 locations have allowed Hart to establish 6 complimentary “service circles” that slightly overlap and allow Hart to deliver oilfield site set-up services and equipment rentals efficiently to its customers as well as respond quickly to requests for service or repairs to its equipment when required.

Early on, Hart realized that the uniqueness of its approach warranted patent filings for equipment as well as industrial designs. With approximately 25 equally divided between Canada and the US, the practice both cements Hart’s reputation as an innovator as well as protect the Company and Enterprise shareholders from interlopers.

There are always interlopers.



It should also be noted that Hart does not sell the custom equipment. Hart is constantly developing equipment to add to its robust and state of the art rental pool: And all with
safety the primary consideration.

Just as with all the Enterprise Group’s subsidiaries, attention to detail is a given. Reactive and proactive to customer needs is what cuts it out of what is already a small herd. Whether resource, municipal needs, pipelines or any other infrastructure pursuit, that word - infrastructure - should be reflected to a greater or lesser degree in every portfolio. US peers are hitting new highs and others, such as Enterprise’s share price is being wrongly assaulted by a volatile oil price.

The bottom line is that over the years Enterprise has made savvy, money making purchases and sales. TC Backhoe sold in 2016 for approximately C$20 million. The Company was purchased in 2007 for C$12 million and under the Enterprise umbrella generated $150 million. The sale was done during the recent downturn, but had been planned previously and drastically lowered and improved the Company’s financials.

Having successfully steered through a blistering downturn, which seems to have unfairly punish a stock that has a breakup of C$0.85 but is trading at C$0.30, it seems a good addition to a junior portfolio.

Investors will also note that as the Company is traded on the TSX that adds to a list of bonafides to Enterprise that investors would be wise to take stock.



Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated ten thousand dollars for its efforts in distributing the TSX:E profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[WADA Lifts CBD Ban for Professional Athletes and their Doctors]]>Thu, 12 Oct 2017 08:02:09 ESThttp://www.baystreet.ca/articles.aspx?id=38458
The World Anti-Doping Agency (WADA) just removed hemp-derived cannabidiol (CBD) from its 2018 List of Prohibited Substances, freeing up athletes in the largest international athletic associations in the world like the IOC and FIFA as well as major sports leagues like UFC, NCAA, NFL, NBA, NHL, MLB, and many more to use CBD-infused products as to treat pain and inflammation based disorders.

As WADA is a global governing body, now athletes around the world can use CBD to treat pain, inflammation and injuries, without the risk of league suspension or a loss of sponsors. Professional athletes around the world can now use Phivida’s CBD infused functional foods and natural health brands, free from WADA restrictions, for the first time in the history of competitive sports.

Cannabinoids have just got mainstream, starting with the major leagues. But it’s investors, and CBD-infused infused functional foods and natural health products brands that stand to benefit the most.

According to Allied Research, the global anti-Inflammatory therapeutics market is projected to top $106 Billion USD by 2020, dominated by OTC drugs like Ibuprofen ($14.2 billion USD by 2022). The US opiate drug as an additional $17.7 billion USD by 2021 dominated by Oxycontin, Percocet and Vicodin. Both the NSAIDs and opiate markets are dominated by pain and inflammation pharmaceutical mogul Bayer (BAYN.DE), with a market capital of over $96 billion.

Cannabidiol is widely studied as a powerful anti-inflammatory and was even part of a US Department of Health patent application for anti-oxidant and neuroprotectant properties.

RISING DEMAND FOR CBD-INFUSED PRODUCTS

Timing the market is vital for maximizing investment returns. There is no better example of fortunate timing than WADA’s announcement coinciding with the launch of Phivida Holdings Inc.’s CBD-infused functional foods and natural health products, and the filing of prospectus for an initial public offering and an application to list its class A shares on the Canadian Securities Exchange (CSE).

As a premiere CBD brand, Phivida is perfectly positioned to capture a leadership market share in this emerging global natural health products market. The Phivida IPO offers investors with exposure to three major growth trends within a global health and wellness $1 Trillion USD in 2017.

Bloomberg predicts US cannabinoid products as a $50 billion USD market by 2020. Within the cannabinoids market, Phivida has created its own unique products category – functional CBD edibles.

High Times magazine produces a top ten edibles list and this year six of them were cannabinoid infused beverages. Phivida specializes in the CBD beverages avoiding a saturated confectionary soft drinks market with functional CBD iced teas, CBD protein shakes and CBD vitamin juices.

Health care practitioners, and now sports medicine professionals, and major nutraceutical distributors cite the paradigm shift from chemical based pharmaceuticals to phytonutraceuticals.

Supplements as a whole market is exploding, having gone from a $37 billion US estimate in 2015, to an expectation of $220 billion globally by 2022.

Nutrition Business Journal cites the two fastest growing categories as; meal replacements (14.8%) and sports nutrition (11.6%), two flagship CBD product lines at Phivida – both infused with a high dose of cannabidiol. Phivida’s nanoencapsulation technology loads CBD into a protective, hydrophilic, liposomal membrane that bonds better with cells. The result is a faster acting longer lasting absorption rates, with up to 400% more bioavailability and a timed release for enhanced duration in the bloodstream, and solubility.

Functional foods have surpassed traditional food topping a $100 billion USD back in 2015. The functional food industry is in the process of a massive consolidation as over $10 billion USD of new M&A deals were completed in 2016 alone.

Major food companies are acquiring new organic and functional food brands at a staggering rate, lead by multi-national conglomerates such as Hains Celestial (NASDAQ: HAIN), PepsiCo (NYSE:PEP) and General Mills (NYSE:GIS).

It’s no wonder that major retailers in both the grocery sector, and the nutritional supplements space are champing at the bit to grow their selection of products for consumers.

WADA’s prohibition lift may be the catalyst needed for supplement giant GNC Holdings Inc. (NYSE:GNC) to get its year back on track. Having fallen from over $20 to just over $8 within the year, the ability to introduce new lines of nutritional supplements with pain relieving qualities could be a shot in the arm for GNC.

Whereas major grocery and pharmacy chains, such as Canadian retail giant Loblaw Companies Inc. (TSX:L)(OTC:LBLCF), which owns the well-established Shoppers Drug Mart chain. Unlike GNC, which to-date has been reluctant to carry CBD products in-store, Shoppers Drug Mart has been very open about its willingness to carry CBD and marijuana-related products on its shelves.

It’s still to be determined when and if that same level of acceptance will be seen on the US side of the border. GNC currently doesn’t carry any CBD-infused products, selling only hemp proteins as a remotely close cousin. Nor is CVS Health Corporation (NYSE:CVS), yet.

Online mega-retailer Amazon.com Inc. (NASDAQ:AMZN) is already selling CBD products. On track to hit the very first $1 trillion valuation, Amazon is ahead of the curve on the blossoming CBD sector.

Whole Foods CEO John Mackey stated he would support cannabinoid products sold in Wholefoods “if only the plant was legal to use and the local community approved.”

Not only is CBD-Hemp Oil extract legal under the Farm Bill, but WADA’s new rules has the potential for a massive demand from professional athletes, sports medicine practitioners and alternative health care practitioners and the everyday active health conscious consumer. It looks like John might get his wish.

Plant-based supplements like CBD are no longer limited to the estimated 17,500 licensed alternative health care practitioners, as majority of supplements are now sold through big box FCMD (food, club, mass and drug) retail locations.

Walgreens, CVS and Walmart combined for a total of 27,087 on-site pharmacists at 15,208 stores across the United States. With Amazon’s acquisition of Wholefoods earlier this year, it’s clear that the majors are looking to capitalize on the health-conscious consumer.

Now it’s a matter of CBD’s true market infiltration to take hold, and for producers to begin stocking only the best CBD infused FFNHP formulations.

Primed and ready to supply these retailers with timely product, Phivida boasts an entire line of CBD functional foods and natural health products, doctor formulated for enhanced athletic performance and everyday preventative health for active families.

INDUSTRY AND ORGANIC ADVANTAGE

Totally legal, and boasting a laundry list of health benefits, cannabidiol (CBD) is making waves through the food and beverage industry in the form of several new products.

So it’s no wonder that any new producer of CBD products will want to seek out the expertise of those already familiar with the food and beverage industry.

Assembling an impressive array of talent, Phivida’s management team is built to master not only its formulation, but also its branding and retail distribution.

Among the names on the company’s deck are Directors Bill Ciprick and James Bailey, who each come with decades of branding and distribution experience for industry heavy-hitters, such as Proctor and Gamble Health Care, and Red Bull Canada.

But for the consumer, the most important aspect to consider beyond retail availability is that of the product’s organic, whole-plant blends and formulations.

Phivida infuses full-spectrum CBD Hemp Oil extracts into special blends of functional foods and natural health products (FFNHP). All nanoencapsulated CBD used in Phivida’s products is hemp-derived from licensed hemp farms and federally legal and eligible for sale in any retail channel.

The company’s CBD-infused functional beverages are nanoencapsulated for enhanced bioavailability, and doctor-formulated for targeted outcomes. Phivida boasts quality-, and safety-tested products that are cGMP manufactured to the highest quality assurance standards.

Phivida CBD Vitamin Drinks use certified organic and plant-based ingredients. Phivida’s CBD infusions are also vegan, gluten- and soy-free with no sugar added and contain at least 35% RDA of Vitamin B complex and Vitamin C.

Other key sports performance ingredients include premium electrolyte replacements, glutamine for muscle, bone and joint repair, resveratrol for added anti-oxidants, blended in an all-natural fruit and vegetable puree with no artificial colours or flavours added.

Former President of the BC College of Naturopaths, Dr. Brian Martin, states; “Phivida offers legal, clinical grade, CBD, third-party tested, and safe for practitioners to recommend to athletes and patients.” Marijuana is federally illegal in the United States, but hemp provides a legal option for clinicians. WADA’s new ruling now opens CBD to team physicians, physiotherapists, nutritionists and kinesiologists. “Phivida is a high-quality brand for athletes who need healthier, non-addictive treatments for pain and inflammation,” said Dr. Martin.

WADA’s now-positive stance on CBD represents a great opportunity for Phivida. Competitive athletes in high-impact sports like football, hockey and mixed martial arts are often plagued with a lifetime of debilitating physical injuries and mental health conditions.

Phivida’s CBD infusions give athletes, their trainers, and medical staff a whole-plant nutraceutical alternative to highly addictive opiate pharmaceuticals to treat chronic pain and inflammation from these injuries and afflictions.

ATHLETIC ENDORSEMENT

Earlier this year, the New York Times published a neuropathology study that found that 99% of former NFL players tested positive for Chronic Traumatic Encephalopathy (CTE). The NFL supports the NFL Players Association’s (NFLPA) study on the use of cannabinoids to treat chronic pain inflammation based disorders, like CTE, according to a Sports Illustrated article published on August 1st, 2017.

The NFLPA was coincided by the launch of the Your Mind Your Body Campaign designed to equip current and former players with the tools needed to achieve a healthy lifestyle, both physically and mentally and encourages an open dialogue on pressing health and safety issues, including CTE, and mental health.

Use of cannabinoid-based alternatives to opiates is not a new issue for the NFL. Many former players have become advocates for CBD as alternatives to narcotics, including former Baltimore Raven Eugene Monroe, Denver Bronco Jake Plummer, Chicago Bear Jim McMahon, and Ricky Williams who publicly stated a belief that “60-70% of all NFL athletes use medicinal marijuana”.

Despite the fact that both the NFLPA and NFL endorse a study of marijuana as a potential pain-management tool, the NFL currently suspends players who test positive for the drug and modified the threshold for a positive test for marijuana (i.e. THC). Finally, WADA’s new adoption of CBD as an approved substance, gives the NFL and its players hope for immediate relief, without controversy.

Phivida’s CBD-infused functional foods and natural health products are formulated with a special blend of nutraceuticals for enhanced athletic performance, and infused with a therapeutic dose of nanoencapsulated cannabidiol from hemp.

"This pain is never going away. My body is damaged," Eugene Monroe, 30, stated in a Washington Post article. "I have to manage it somehow. Managing it with pills was slowly killing me.”

With the lift on the CBD ban, WADA is finally taking sensible action on behalf of the athletes it is tasked to protect.

“Cannabidiol is no longer prohibited,” WADA said, maintaining that THC will remain as a banned substance. WADA cited the reason for the removal of cannabidiol from the banned list was because “it is not a cannabimimetic and does not mimic the effects of THC.”

WADA further clarified: “THC is still a prohibited substance.”

THC or tetrahydrocannabinol is the psychotropic chemical compound in marijuana that contributes to euphoric effects. Many CBD products on the market are marijuana derived and contain THC.

Purity levels in CBD-infused products will give an industry advantage to those producers that can utilize the most CBD, without delivering any THC.

Phivida’s nanoencapsulated CBD-Hemp Oil extracts, edibles and infusions, are federally legal, derived from Farm-Bill-compliant farms, and are now 100% WADA-compliant sources for cannabidiol. As well, they’re coming to a store near you.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated eight hundred dollars for its efforts in distributing the Phivida article. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
]]>
<![CDATA[Valeant (VRX) Cleans Up its Debt]]>Thu, 12 Oct 2017 07:40:19 ESThttp://www.baystreet.ca/articles.aspx?id=38457
Valeant, on October 3, issued a $1-billion debt offering that lower the total upcoming maturities.

Valeant priced its $1-billion principal amount of 5.5% senior notes due in 2025. It will use the proceeds to roll over existing debt. The issuance is not trivial: the lower interest will save the company money while simultaneously pushing out the maturity date.

The low interest rate offered suggests the market has a healthy appetite for Valeant’s debt, so the fear of any bankruptcy is now off the table. Valeant now has around $26 billion in debt and $24 billion net of cash. In June, the company’s net debt was $26.7 billion. The sale of Dendreon raised $811 million, while iNova brought in $923 million. The net effect is that Valeant will have $3.9 billion maturing in 2020.

Assuming Valeant generates $1 billion in free cash flow, the company’s interest on debt in 2020 are covered. It sets the stage for refinancing for the debt due in 2021 and beyond.
]]>
<![CDATA[Athersys Hikes on MultiStem Hookup with Japanese Firm ]]>Wed, 11 Oct 2017 12:24:52 ESThttp://www.baystreet.ca/articles.aspx?id=38456Based on the agreement, Athersys and NCLi will engage in technology transfer activities at NCLi’s facility in Japan, and NCLi will begin contract manufacturing support for commercial development of the product in Japan. Athersys’ collaborator, HEALIOS K.K. (Healios), has an exclusive license to develop and market MultiStem in Japan for ischemic stroke, and is currently conducting its registrational clinical study, TREASURE, in Japan.

A news release issued Wednesday claimed therapeutic treatment with MultiStem may extend the stroke treatment window to 36 hours from the current three to four-and-a-half hours with existing standard of care, which would enable many more stroke patients to receive treatment than under the current standard of care and may also meaningfully enhance patient recovery.
Currently, there are nearly 17 million people that suffer a stroke globally and, on average, someone in the United States has a stroke every 40 seconds.
Athersys shares gained 11 cents, or 4.9%, midday Wednesday to $2.34, within a 52-week trading range of $1.02 to $2.63.
]]>
<![CDATA[Delta Gains Altitude on Q3 Earnings]]>Wed, 11 Oct 2017 11:12:22 ESThttp://www.baystreet.ca/articles.aspx?id=38455The number-two U.S. airline reported adjusted earnings per share of $1.57, beating analysts' expectations of $1.53 a share for a quarter that ended with hurricanes that crippled operations.

Earnings per share were about 8% lower over the year-earlier period.

The airline posted quarterly revenue of $11.06 billion, slightly higher than expectations for $11.03 billion in the three months ended in September.

Delta's passenger revenue per available seat mile — a key income metric — rose 1.9%, in line with the airline's updated forecast earlier last month. It said it expects a 2% to 4% increase in passenger unit revenue in the fourth quarter, but warned that higher fuel costs would likely crimp operating margins for the last three months of the year.

Delta posted higher revenue in domestic and Latin American and trans-Atlantic operations, despite powerful storms in the Southern U.S. in August and September.

Delta executives will likely address the impact from deadly storms that hit carriers' hubs late this summer, as well as a bitter trade dispute between two Delta suppliers, Boeing and Canada's Bombardier.

Hurricane Irma, which struck Florida and Delta's hub in Atlanta, forced the airline to cancel more than 2,000 flights.

Delta shares began Wednesday’s trading up 37 cents to $53.07
]]>
<![CDATA[BlackRock Rocks Markets on Q3 Figures ]]>Wed, 11 Oct 2017 10:42:55 ESThttp://www.baystreet.ca/articles.aspx?id=38454Total assets under management rose 17% to nearly $6 trillion as net inflows easily beat Wall Street expectations.

Here's how the company's results compare to Wall Street's expectations: EPS came in at $5.92 per share, compared with $5.56 expected. Revenue was $3.233 billion versus $3.096 billion expected.

Total assets under management registered at $5.977 trillion versus experts’ projected $5.94 trillion.
Net inflows were $96 billion versus $71.62 billion expected.
BlackRock also said its iShares exchange-traded funds business saw $52.3 billion in long-term net inflows, led by $33.1 billion in equity inflows. Assets under management for iShares totaled $1.640 trillion, accounting for 27% of BlackRock's total assets.

The company said cash assets rose 6 percent from a year earlier to $425.4 billion.

"One of the greatest problems we still have in the world is how much money is sitting on the sideline," according to CEO Larry Fink. "Even in places like Japan, there's $5 trillion in cash earning negative return. In Germany 72% of savings are in bank accounts. We're seeing some of that unlocked (and), we're seeing people put some of that money to work."

The company's stock has been on fire this year, advancing 21.5%. By comparison, the overall S&P 500 is up about 14% in the period. BlackRock shares have also outperformed the financials sector, which is up 13% in 2017.
BlackRock shares opened Wednesday up $2.80 to $468.29 ]]>
<![CDATA[Emblem Positioned to be Disruptive in the Medical Cannabis Industry]]>Wed, 11 Oct 2017 08:44:45 ESThttp://www.baystreet.ca/articles.aspx?id=38453
First, it has become apparent that for the foreseeable future, a few select Canadian marijuana companies will lead the sector growth, particularly over the US.


Second, the virtually unlimited growth in the space will and is being realized through the pharmaceutical developments, particularly in the pain, sleep and anxiety markets. Pain markets alone are $60 billion and will rise over 30% to $83 billion by 2024. Pain and sleep markets are two of the largest component markets.

Key to this growth at companies such as Emblem (TSXV:EMC) is when society embraces marijuana as what could well be the first line of defense and treatment for many afflictions, including the devastating opiate crisis.

“Emblem is focused on developing mainstream medical therapies to deliver consistent, 12-hour relief, with reduced side effects.,” states Gordon Fox, CEO Emblem Corp. “Canada is one of the few jurisdictions in the world –including the USA--with a path to regulatory approval of cannabinoid based medication. ACMPR has mechanisms for approval and these mechanisms are currently being expanded. The Canadian medical community can participate in research and clinical trials and share data and results across provincial boundaries.

With our recently announced exclusive arrangement with CanntabTherapeutics, Emblem is executing to plan.”

The Canntab Deal

Very simply, Canntab has the proprietary sustained release formulation: Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marijuana.

Canada is one of the few jurisdictions in the world with a path to regulatory approval of cannabinoid based medication.

- The current medical cannabis market in Canada is about $400 million. It is searching for better dosage formats. Simple oils have grown to about 35% of the market in less than a year. More appropriate dosage formats are expected to have comparable effects in the market.

- Currently, Cannabis tends to require re-dosing. A titratable, sustained release formulation would have substantial appeal in the chronic neuropathic pain market. Anecdotally, that segment represents a reasonable percentage of the current$400 million medical cannabis market.

- The Canadian non-cannabis chronic pain pharmaceutical market is over $500 million and dominated by opioids and is expected to reach $42.16 billion worldwide by 2021. A cannabinoid based sustained release product has potential to enter that market.



From Emblem’s October 3rd Press Release:

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use.

The Agreement grants to Emblem the exclusive right in Canada to Canntab’s patents and know-how for the purpose of developing, commercializing, using, selling, and offering the Sustained Release Product for sale under the Emblem brand. The License does not include the right to import or export the Product. The Sustained Release Products will be manufactured by Emblem or by Canntab, after Canntab receives appropriate licensing allowing such manufacture.

As per other Royalty Agreements in the Pharmaceutical Sector terms weren’t disclosed other than ‘double digit” royalty. To be clear this relationship with Canntab is extremely favorable to Emblem.

It cannot be overstated how important a develop this is for patients. Instead of waiting 5-10 years for a therapy to get to patients, cannabis based products take mere months. There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including (i) chronic pain (ii) nausea, (iii) anxiety and sleep disorders, and (iv) spasticity in patients with Multiple Sclerosis.

The Global Opiate Crisis

While therapies will address particular conditions, anecdotally many patients know and have expressed the efficacy, ease of use and lack of side effects in pain management particularly.

Emblem plans to bring products to deal with neurological pain by fall 2018. Once the 12- hour delivery protocol is established, many afflictions can be addressed via the proper strain and titration.

Investors need to embrace the potential of this market and acquire some exposure. Choose carefully as there are many companies who have and will likely fail or price themselves out of the market.

Emblem’s business plan sets three divisions to be profit centres. From ongoing reasonable to maximum growth:

- Dried flower is the commodity space which provides superior, but generic product

- High quality strains (think aged single malt scotch versus JW Black) for the aficionado

- Top quality strains for ongoing therapeutics’ development.

Margins increase exponentially from dried flower to medical strains. Emblem (TSXV:EMC) is focused on the two markets above dried flower, although will be a major force in all three.

Marijuana Market Maturing Slightly. Invest Carefully, but Invest

The Marijuana space has matured somewhat from mining guys seeing a quick turn in fortunes by announcing some hair-brained participation to get their languishing stock prices up.

Then there the companies who conclude that more marijuana is better and are growing as much as they can.

Finally, there are a few companies, such as Emblem that have a solid growth plan and are not afraid to state their corporate intentions. Many comparisons are made to the UK’s GW Pharma as the direction a developing company should travel.

GW’s Sativex is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. GW’s ADS on NASDAQ in 2013 came at $8.90. Last trade at this writing was $114.07.

Fun Facts

- Some plant biologists got their early weed (60’s, 70’s) experience by serving time for possession, etc.

- Lots of anecdotal evidence that Big Pharma continues to pay doctors to keep their products at the forefront

The five companies that disclosed what they paid doctors over a six-month period (July to December 2016) were:

- AbbVie (NYSE:ABBV) : $4,104,000

- Novartis (NYSE:NVS) : $3,645,026

- Amgen (NASDAQ:AMGN) : $2,365,000

- Bristol-Myers Squibb (NYSE:BMY) : $1,388,187

- Gilead (NASDAQ: GILD) : $539,761



That alone should give Marijuana companies such as Emblem a place in your speculative portfolio.

Oh, yes. 10 percent of patients suffer from Trypanophobia. That fear keeps 20 percent of that number to never seek medical attention. Look it up…

Perhaps with the inevitable insertion of Marijuana based therapies should reduce or eliminate that number.

And how would Big Pharma ‘payola’ doctors for such a readily available and efficacious therapy? Bueller?

Next couple of decades should be interesting; with less pain, more sleep, relief from chronic disease as well as lives saved.

Legal Disclaimer/Disclosure: This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated four thousand dollars for its efforts in distributing the TSXV:EMC profile on its web site and distributing it to its database of subscribers. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. ]]>
<![CDATA[AnaptysBio Makes Waves on Trial Data ]]>Tue, 10 Oct 2017 03:25:01 ESThttp://www.baystreet.ca/articles.aspx?id=38452Said CEO Hamza Suria, “we are very encouraged by the efficacy results to date in this Phase 2a study, which exemplify our strategic focus on developing first-in-class anti-inflammatory antibody therapeutics to help patients suffering from debilitating inflammatory diseases.

“We look forward to further advancing the development of ANB020 for the treatment of patients with atopic diseases.”

The Phase 2a study is currently ongoing and EASI scores will be assessed for each patient up to 140 days post-ANB020 treatment. The company plans to report full data from this trial at a medical conference following study completion.

AnaptysBio is a clinical-stage biotechnology company developing what it calls “first-in-class antibody product candidates focused on unmet medical needs in inflammation”.

Its shares neared the close Tuesday up in the stratosphere, leaping in price $31.02, or 88.6%, to $66.02.
]]>
<![CDATA[Wal-Mart Hikes on Share Buyback Program]]>Tue, 10 Oct 2017 11:30:29 ESThttp://www.baystreet.ca/articles.aspx?id=38451Wal-Mart also unveiled a $20-billion share repurchase program to replace its existing plan. The company says the new authorization will be used over a two-year period.

The big-box retailer explained it will continue to focus on remodeling existing stores and incorporating "digital experiences" in place of building new locations.

Ahead of its annual investor day in Bentonville, Arkansas, Wal-Mart said it expects its U.S. e-commerce business to grow sales by roughly 40% in fiscal 2019. Online transactions surged 60% during the second quarter of this year, the retailer declared in August.

The company still expects adjusted earnings per share for the fiscal year 2018 to fall between $4.30 and $4.40.

For fiscal 2019, Wal-Mart said it expects earnings to increase about 5% year over year. Net sales for fiscal 2019 are expected to grow close to 3%, driven by same-store and e-commerce sales growth, the company added.

In fiscal 2019, across the U.S., Walmart will open fewer than 15 Supercenters and fewer than 10 of its Neighborhood Markets.

For fiscal years 2018 and 2019 combined, Wal-Mart is calling for capital expenditures to be about $11 billion, with e-commerce investments going toward enhancing the retailer's supply chain. Wal-Mart's international business will also invest more in fulfillment capabilities.

Shares in Wal-Mart galloped $3.53, or 4.4%, to $84.06
]]>